MRRPhysical AI
intelligence
← Company intelligence

Robot maker · registered

Multiply Labs

Corporate marketlabCurated record
multiplylabs.com

Proprietary software stack orchestrating a fleet of Universal Robots (UR) collaborative arms in parallel biomanufacturing clusters; integrates NVIDIA Isaac GR00T N foundation models (announced Jan 2026) for advanced robotic dexterity; modular architecture targeting 100x patient doses per square foot vs. manual cell therapy manufacturing.

HeadquartersSan Francisco, US
Founded2016
Corporate funding$36M
Team11-50
Deployments8
Open roles8
01

Company overview

Identity and operating footprint

Company typeRobot maker
Market segmentCorporate
StageSeries A
FoundersFred Parietti (Co-founder), Alice Melocchi (Co-founder), Joe Wilson (Co-founder), Tiffany Kuo (Co-founder)
Regions servedNorth America
Countries deployedUS
Service footprintRobotic biomanufacturing systems-as-a-service for cell and gene therapy; operates from San Francisco; named pharma/biotech clients include AstraZeneca, Legend Biotech, and GenScript.
Last reviewed2026-07-05
MX

Robot models

Specifications remain vendor-claimed

Machinelab

Robotic Biomanufacturing Cluster

  • Four UR collaborative robot arms operating in parallel; delivers 74% reduction in cell and gene therapy manufacturing cost; modular cleanroom-compatible architecture

    Vendor-stated performance metrics for the biomanufacturing cluster integrating UR cobots with proprietary orchestration software

    Claim source
DP

Deployment log

Announced and cited only

AnnouncedCustomerSiteCountryCountEvidence
2026-01-27AstraZenecabiopharmaNot listedNot disclosedAnnouncement
2025-01-01Kyverna Therapeuticscell_therapy_manufacturingUSNot disclosedAnnouncement
2024-10-02Legend BiotechbiopharmaUSNot disclosedAnnouncement
2024-09-25Undisclosedpharmaceutical_manufacturingUSNot disclosedAnnouncement
2024-05-14Retro Biosciencescell_therapy_manufacturingUSNot disclosedAnnouncement
2024-04-23GenScript BiotechbiopharmaUSNot disclosedAnnouncement
2024-04-23Stanford Medicine (LCGM)medical researchUSNot disclosedAnnouncement
2024-04-01Undisclosedpharmaceutical_manufacturingUSNot disclosedAnnouncement
CA

Funding history

Publicly announced rounds

Investors on recordCasdin CapitalLux CapitalFounders Fund (Pathfinder)Fifty YearsGarage Capital
HR

Hiring signal

Public job board · 2026-07-13

Open roles8

Hiring is an operating signal, not deployment evidence. Roles are refreshed from the company’s public careers system.

Senior / Staff Robotics Research Scientist - Dexterous & Mobile ManipulationAdvanced Software R&D · San FranciscoExecutive Assistant to the CEOBusiness Operations · San FranciscoVP Software Engineering, Robotics & SystemEngineering Leadership · San FranciscoOpen Applications at Multiply LabsGeneral Interest · San FranciscoScientist IIGeneral Interest · San FranciscoRobotics Field EngineerRobotics Software · Los AngelesRobotics Software Engineer IIRobotics Software · San FranciscoSenior / Staff Robotics Software EngineerRobotics Software · San Francisco
TL

Company timeline

Milestones and announcements

2026-01-13Partnership with NVIDIA to integrate Isaac GR00T N models into biomanufacturing platformNo source
2024-09-25Announced collaboration with Legend Biotech (Carvykti CAR-T therapy) on cell therapy automationNo source
2024-04-01Announced collaboration with GenScript Biotech on cell isolation automationNo source
2021-04-14Raised $20M Series A led by Casdin Capital; total funding exceeded $25MNo source
2016-01-01Founded in San FranciscoNo source
SC

Source ledger

14 unique public sources

01
SEC Form D: $11,100,000 sold of $11,100,000 offeringSEC EDGAR · retrieved 2026-07-05
02
Multiply Labs Announces $20 Million Series A to Pioneer Robotic Manufacturing of Individualized DrugsBusinessWire · retrieved 2026-07-05
03
SEC Form D: $2,252,500 sold of $2,252,500 offeringSEC EDGAR · retrieved 2026-07-05
04
SEC Form D: $2,805,000 sold of $2,805,000 offeringSEC EDGAR · retrieved 2026-07-05
05
Robotics Transforms Cell Therapy: Multiply Labs Drives Staggering 74% Cost Reduction, Unlocking Global Patient AccessBusinessWire · retrieved 2026-07-05
06
Multiply Labs Announces New Collaboration to Automate Cell Therapy Manufacturing with RoboticsBusiness Wire · retrieved 2026-07-05
07
Robotics Transforms Cell Therapy: Multiply Labs Drives 74% Cost ReductionRoboticsTomorrow · retrieved 2026-07-05
08
Legend Bio and Multiply Labs partner to improve CAR-T manufacturingBioProcess International · retrieved 2026-07-05
09
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend BiotechBusinessWire · retrieved 2026-07-05
10
Multiply Labs and Retro Biosciences Announce an $85 Million Partnership to Advance Cell Therapy Manufacturing for Age-Related DiseasesBusiness Wire · retrieved 2026-07-05
11
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy ManufacturingGenScript · retrieved 2026-07-05
12
Multiply Labs Announces Upcoming Collaboration with Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM)Business Wire · retrieved 2026-07-05
13
Multiply Labs and GenScript Biotech Corporation Collaborate to Automate Cell Therapy ManufacturingPRNewswire · retrieved 2026-07-05
14
NewsroomMultiply Labs · retrieved 2026-07-05